Paper: Analysis of Short Selling in Canada

Paper

Short Selling in Canada: Regulations are Weak and a New Path Forward is Needed to Reduce Systemic Risk 

Based on our research, it is clear that IIROC’s largely non-interventionist approach and its focus on maintaining liquidity have made Canadian companies attractive targets for short campaigns. From 2015 to 2018 there was an increase in the number of short campaigns in Canada, while generally in other jurisdictions there was a decrease. Additionally, the number of short campaigns in Canada is utterly disproportionate to the size of our capital markets when compared to the United States, the European Union and Australia (as examples). The reason for this seems clear: short selling regulations in Canada are out of step with regulations in those other jurisdictions – see Schedule A attached hereto. As a result of inherent weaknesses in the Canadian short sale regulatory regime, short sellers may well be attracted to the Canadian capital markets.

PDF (164 Pages): Paper Analysis of the Short Selling Landscape of Canada

Article: CEO fires back at short-seller Citron on live TV: ‘Mr. Left is dead wrong’

Article - Media

CEO fires back at short-seller Citron on live TV: ‘Mr. Left is dead wrong’

Berkeley Lovelace Jr.

CNBC, 15 May 2017

Exact Sciences Chairman and CEO Kevin Conroy fired back at a bearish assessment made by Citron Research’s Andrew Left, who predicted a long-term drop in the cancer testing company’s stock to a near-zero single digit.

Citron said in a report on Monday that Exact Sciences’ Cologuard cancer test, an at home screening for colon cancer, is “inferior” and shouldn’t be pitching it as an alternative to a colonoscopy.

Read full article.

 

Comment: Andrew Left’s Citron appears to be a front for naked short sellers.